27 patents
Utility
Bacteria Engineered to Secrete Active Proteins
19 Oct 23
Recombinant bacteria capable of producing effector molecules, which are secreted as therapeutically active polypeptides, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, cancer and/or metabolic diseases, are disclosed.
Dean Falb, Vincent M. Isabella, Paul F. Miller, Adam B. Fisher, Ning Li, Jose M. Lora
Filed: 30 Sep 21
Utility
Recombinant Bacteria for Production of D-lactate And/or L-lactate and Uses Thereof
21 Sep 23
The present disclosure provides recombinant bacteria for production of D-lactate and/or L-lactate.
Ning Li, Anna Sokolovska, Francisco Quintana, Liliana Sanmarco
Filed: 6 Aug 21
Utility
Microorganisms Programmed to Produce Immune Modulators and Anti-cancer Therapeutics In Tumor Cells
20 Jul 23
Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
Filed: 2 Aug 22
Utility
Recombinant Bacteria Engineered to Treat Diseases Associated with Uric Acid and Methods of Use Thereof
6 Apr 23
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off.
Vincent M. Isabella, Sean Cotton, Jian-Rong Gao, Teodelinda Mirabella, Christopher George Bergeron
Filed: 25 Feb 21
Utility
Bacteria Engineered to Treat Disorders In Which Oxalate Is Detrimental
23 Mar 23
The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme.
Vincent M. Isabella, David Lubkowicz, Michael James
Filed: 14 Jan 21
Utility
Recombinant Bacteria Engineered to Treat Diseases Associated with Methionine Metabolism and Methods of Use Thereof
23 Mar 23
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off.
Vincent M. Isabella, Sean Cotton
Filed: 12 Feb 21
Utility
Recombinant Bacteria Engineered to Treat Diseases Associated with Methionine Metabolism and Methods of Use Thereof
2 Mar 23
The present disclosure provides host cells, e.g., bacterial cells, that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with methionine metabolism in a subject.
Dylan Alexander Carlin, Vincent M. Isabella, Jonathan McMurry, Theodore Carlton Moore, III, Mylene Perreault, Seth Ritter, Nathan Schmidt, Mark Simon
Filed: 11 Aug 22
Utility
Bacteria Engineered to Treat Diseases That Benefit from Reduced Gut Inflammation And/or Tightened Gut Mucosal Barrier
9 Feb 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Filed: 8 Jun 22
Utility
Microorganisms Engineered to Reduce Hyperphenylalaninemia
17 Nov 22
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Kristin ADOLFSEN, Per GREISEN, Isolde CALLIHAN, Adam LAWRENCE, James SPOONAMORE, Jay KONIECZKA
Filed: 3 Jun 22
Utility
Optimized Bacteria Engineered to Treat Disorders Involving the Catabolism of Leucine, Isoleucine, And/or Valine
17 Nov 22
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patients internal environment and respond by turning an engineered metabolic pathway on or off.
Ning Li, Jian-Rong Gao, Philippa Jane Reeder Morrison, Christopher George Bergeron, Dylan Alexander Carlin, Laura K. Stone, Alex C. Tucker, Patrick M. Boyle
Filed: 19 Jun 20
Utility
Biosynthesis of Enzymes for Use In Treatment of Maple Syrup Urine Disease (Msud)
3 Nov 22
Provided in this disclosure, in some embodiments, are methods and compositions for treating maple syrup urine disease (MSUD) and other conditions characterized by excessive branched-chain amino acids.
Patrick Boyle, Dylan Alexander Carlin, Rishi Jain, Ryan Putman, Laura Stone, Alex C. Tucker, Kolea Zimmerman
Filed: 19 Jun 20
Utility
Enumeration of Genetically Engineered Microorganisms by Live Cell Counting Techniques
18 Aug 22
Genetically engineered microorganisms, e.g., genetically engineered bacteria, compositions and formulations thereof, as well as methods for characterizing, dosing, and determining the activity of the bacteria, compositions, and formulations, e.g., using a live cell counting method are disclosed.
Eugene ANTIPOV
Filed: 29 Apr 20
Utility
Bacteria Engineered to Treat Disorders In Which Oxalate Is Detrimental
28 Jul 22
The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme.
Vincent Isabella, Dean Falb, Cami Leigh Anderson, Paul Miller, Yves Millet, Jonathan Kotula
Filed: 2 Feb 22
Utility
Bacteria Engineered to Treat Metabolic Diseases
21 Jul 22
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Elizabeth Rowe, Yves Millet, Adam B. Fisher
Filed: 26 Jan 22
Utility
Synergistic Combinations of Arginine-producing Bacteria And/or Ammonia-consuming Bacteria and Checkpoint Inhibitors and Methods of Use Thereof
21 Jul 22
Disclosed herein are synergistic compositions and methods using arginine-producing bacteria and/or ammonia-consuming bacteria in combination with a checkpoint inhibitor for use in treating cancer.
Jose M. Lora, Roger Geiger
Filed: 13 May 20
Utility
Bacteria Engineered to Treat Disorders Involving the Catabolism of a Branched Chain Amino Acid
2 Jun 22
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off.
Dean Falb, Paul F. Miller, Yves Millet, Vincent M. Isabella, Jonathan W. Kotula, Alex Tucker
Filed: 10 Dec 21
Utility
Combination Therapies of Microorganisms and Immune Modulators for Use In Treating Cancer
27 Jan 22
Combination therapies comprising a microorganism and an immune modulator, and methods of modulating and treating cancers are disclosed.
Jose M. Lora, Anna Sokolovska
Filed: 8 Nov 19
Utility
Surface Display of Proteins on Recombinant Bacteria and Uses Thereof
2 Dec 21
Recombinant microorganisms, pharmaceutical compositions thereof, and methods of protein display on the cell surface of the microorganisms are disclosed.
Ning Li
Filed: 26 May 21
Utility
Bacteria Engineered to Treat Diseases Associated with Hyperammonemia
17 Jun 21
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
Filed: 16 Dec 20
Utility
Bacteria Engineered to Treat a Disease or Disorder
10 Jun 21
Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
Filed: 17 Dec 20